Svas Biosana S.p.A. (BIT:SVS)
Italy · Delayed Price · Currency is EUR 8.16
-0.02 (-0.24%)
At close: Aug 8, 2025, 5:30 PM CET
Ligand Pharmaceuticals Revenue
In the year 2024, Svas Biosana had annual revenue of 122.29M EUR with 0.54% growth. Svas Biosana had revenue of 63.25M in the half year ending December 31, 2024, with 15.37% growth.
Revenue
122.29M
Revenue Growth
+0.54%
P/S Ratio
0.36
Revenue / Employee
373.97K
Employees
327
Market Cap
43.57M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 122.29M | 656.90K | 0.54% |
| Dec 31, 2023 | 121.63M | 22.12M | 22.22% |
| Dec 31, 2022 | 99.51M | 17.52M | 21.37% |
| Dec 31, 2021 | 81.99M | 4.72M | 6.11% |
| Dec 31, 2020 | 77.27M | -23.22M | -23.11% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Recordati Industria Chimica e Farmaceutica | 2.48B |
| DiaSorin | 1.22B |
| Amplifon | 2.41B |
| EL.En. | 577.19M |
| Philogen | 77.65M |
| Safilo Group | 998.89M |
| GPI S.p.A. | 509.93M |
| Pharmanutra | 116.15M |